Phaseline

Targets › NR3C2

NR3C2 (Mineralocorticoid receptor): drug programs, companies and trials

21 programs from 20 companies in 89 trials: 30 Phase 2, 23 Phase 4, 22 Phase 3, 14 Phase 1; Cardiovascular, Genitourinary, Metabolic and endocrine; next expected readout Nov 2026.

Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates target genes. (UniProt, P08235)

Open in Phaseline: the race on NR3C2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Brigham and Women's HospitalMIB 626 (NMN)
Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
SLC5A2, SLC6A2, GLP1R, UNKNOWN, Tubulin, OPRM1, NR3C2, AGTR1, IL4R, SLC6A4, HTR2A, HTR2CPhase 4Prostate Cancer; Stable Coronary Disease; Allergic Contact Dermatitis; Hypertension …Nov 2026
Yale UniversitySpironolactone
Mineralocorticoid receptor antagonist
NR3C2Phase 4Heart Failure; Intracerebral HemorrhageNov 2026
University of PennsylvaniaSpironolactone
Mineralocorticoid receptor antagonist
NR3C2Phase 4AcneJul 2027
Insud PharmaDrospirenone (LF111)
Mineralocorticoid receptor antagonist; Progesterone receptor agonist
NR3C2, PGRPhase 4Change in Bone Mineral Density; ContraceptionDec 2027
Santhera Pharmaceuticalsvamorolone
Glucocorticoid receptor agonist; Mineralocorticoid receptor antagonist
NR3C1, NR3C2Phase 4Duchenne Muscular DystrophySep 2028
Uppsala UniversitySpironolactone
Mineralocorticoid receptor antagonist
NR3C2Phase 3Heart Failure With Preserved Ejection FractionDec 2026
BayerFinerenone (BAY94)
Mineralocorticoid receptor antagonist
NR3C2Phase 3Chronic Kidney Disease; Left Ventricular Systolic Dysfunction; Primary Membranous Nephropathy; Heart Failure …Apr 2027
Washington University School of MedicineEplerenone
Mineralocorticoid receptor antagonist
NR3C2Phase 3Heart Failure With Reduced Ejection FractionApr 2029
The George InstituteFludrocortisone Acetate
Mineralocorticoid receptor agonist
NR3C2Phase 3Septic Shock; Aneurysmal Subarachnoid HemorrhageJul 2029
Central Hospital, Nancy, FranceEplerenone
Mineralocorticoid receptor antagonist
NR3C2Phase 3Kidney Transplantation for More Than One Year; End-stage Renal DiseaseAug 2031
Assistance Publique - Hôpitaux de Paris9 alpha fludrocortisone
Mineralocorticoid receptor agonist
NR3C2Phase 3Critical Illness Related Corticosteroids Insufficiency–
University Hospital, Strasbourg, FranceSpironolactone
Mineralocorticoid receptor antagonist
NR3C2Phase 3Rheumatoid Arthritis–
Qilu Hospital of Shandong Universityspironolactone
Mineralocorticoid receptor antagonist
NR3C2Phase 2NCOR Gene MutationsDec 2026
Karolinska InstitutetEplerenone
Mineralocorticoid receptor antagonist
NR3C2Phase 2HFrEF - Heart Failure With Reduced Ejection FractionFeb 2027
Massachusetts General Hospitalspironolactone
Mineralocorticoid receptor antagonist
NR3C2Phase 2PreeclampsiaDec 2027
Hospices Civils de LyonSpironolactone
Mineralocorticoid receptor antagonist
NR3C2Phase 2Arrhythmogenic Right Ventricular DysplasiaDec 2027
Massachusetts General HospitalEplerenone
Mineralocorticoid receptor antagonist
NR3C2Phase 2HypertensionMar 2029
National Institutes of Health Clinical Center (CC)Spironolactone
Mineralocorticoid receptor antagonist
NR3C2Phase 2Pulmonary Arterial HypertensionDec 2031
NHS National Waiting Times Centre BoardEplerenone
Mineralocorticoid receptor antagonist
NR3C2Phase 2Myocardial Infarction, Acute–
National Institute on Drug Abuse (NIDA)Spironolactone
Mineralocorticoid receptor antagonist
NR3C2Phase 1Alcohol Use DisorderDec 2026
Mayo ClinicSpironolactone
Mineralocorticoid receptor antagonist
NR3C2Phase 1Thoracic Aortic AneurysmMay 2028

Conditions

Heart Failure (5) Obstructive Sleep Apnea (4) Chronic Kidney Disease (2) Left Ventricular Systolic Dysfunction (2) Chronic Kidney Diseases (2) Hypertension (2) Prostate Cancer (2) Multiple Sclerosis (2) Cardiac Amyloidosis (2) Ulcerative Colitis (2) Pediatric HIV Infection (2) Septic Shock (2)

Modalities

small molecule (21)

Companies

Massachusetts General Hospital (2) National Institutes of Health Clinical Center (CC) (1) Washington University School of Medicine (1) Bayer (1) Yale University (1) University Hospital, Strasbourg, France (1) Assistance Publique - Hôpitaux de Paris (1) Brigham and Women's Hospital (1) NHS National Waiting Times Centre Board (1) Hospices Civils de Lyon (1) Mayo Clinic (1) Karolinska Institutet (1) Santhera Pharmaceuticals (1) Uppsala University (1) Central Hospital, Nancy, France (1) National Institute on Drug Abuse (NIDA) (1) The George Institute (1) Insud Pharma (1) Qilu Hospital of Shandong University (1) University of Pennsylvania (1)

Related targets

SLC5A2 (1) SLC6A2 (1) GLP1R (1) UNKNOWN (1) Tubulin (1) OPRM1 (1) AGTR1 (1) IL4R (1) SLC6A4 (1) HTR2A (1) HTR2C (1) NR3C1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.